Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region

NCT00373607 is registered in ClinicalTrials.gov with Institute of Tropical Medicine, Belgium as lead sponsor.

NCT NCT00373607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00373607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region
Lead sponsor
Institute of Tropical Medicine, Belgium
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2003
Completion date
July 31, 2005
Enrollment
522 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

malaria